Hoth Therapeutics, Inc., a biopharmaceutical company focused on patient-centric therapies, has announced a significant milestone in the regulatory advancement of its lead asset, HT-001. The company has engaged Premier Research to support the submission of an Expanded Access Program (EAP) application. This initiative aims to provide compassionate access to HT-001 for cancer patients experiencing severe skin toxicities from epidermal growth factor receptor (EGFR) inhibitor therapies, addressing a critical unmet medical need. The Expanded Access status is expected to expedite the pathway to commercialization and enhance the generation of real-world data. This move underscores Hoth Therapeutics' commitment to patient care and increases the clinical and commercial potential of HT-001. Investors and partners are advised to monitor updates as the company progresses toward key development milestones.